Bioenvision's primary focus is the acquisition, development and distribution of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: clofarabine (in co-development with ILEX Oncology, Inc.); Modrenal® (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer); and other products in clinical trials. Bioenvision is also developing anti-infective technologies, including the OLIGON technology, an advanced biomaterial that has been approved for certain indications in the U.S.
CONTACT INFO:
Bioenvision, Inc. David P. Luci,
Phone: 212/750-6700
Fax: N/A
www.bioenvision.com
Company Profile
Analyst: N/A Price Target: N/A Time Horizon: N/A Research Established: N/A Rating: N/A ?
Click to trade 24/7
Charts
Charts courtesy of http://portals.wallstreettape.com
Home
Bioenvision's primary focus is the acquisition, development and distribution of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: clofarabine (in co-development with ILEX Oncology, Inc.); Modrenal® (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer); and other products in clinical trials. Bioenvision is also developing anti-infective technologies, including the OLIGON technology, an advanced biomaterial that has been approved for certain indications in the U.S.
Sign Up / Login